AOD-9604

AOD-9604 is a peptide fragment related to human growth hormone, studied for fat metabolism and body-composition research.

Growth hormone influences how fat cells store and release fat. AOD-9604 was designed to focus on the fat-metabolism portion of GH without acting like full HGH.

It is studied for helping shift fat-cell activity toward fat breakdown and away from fat storage.

In practical terms, AOD-9604 is researched for lipolysis, fat metabolism, body-composition research, obesity-related pathways, metabolic function, and fat-cell signaling.

This is not a stimulant, GLP-1 medication, appetite suppressant, or full HGH. It should not be described as a proven human weight-loss drug, the strongest published results are animal and mechanistic; human trials suggested it was generally well tolerated but larger obesity trials did not establish it as an effective approved weight-loss therapy.

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, a modified hGH fragment related to amino acids 177-191, with structural modification intended to preserve GH's fat-metabolism activity while avoiding broader GH effects.

The core research idea is that full HGH influences fat metabolism but also affects IGF-1, glucose metabolism, insulin sensitivity, tissue growth, and other endocrine pathways. AOD-9604 was developed to investigate whether the lipolytic, fat-reducing portion of GH could be isolated without producing the wider endocrine effects of HGH.

Lipolysis means breakdown of stored fat into fatty acids; lipogenesis means creation and storage of fat. AOD-9604 is mainly studied for its potential to increase lipolysis and reduce lipogenesis in fat tissue.

Preclinical research in obese rodents showed AOD-9604 and related hGH fragments reduced body-weight gain, reduced fat mass, increased lipolytic activity in adipose tissue, and influenced fat oxidation. Beta-3 adrenergic receptor pathways may be involved in some of its fat-metabolism effects.

Within Metabolic / Weight Loss, AOD-9604 sits on the fat-cell metabolism side of the category. Different from GLP-1 medications (appetite, gastric emptying, glucose signaling) and from stimulants (short-term energy output). It is researched as a fat-metabolism peptide fragment.

Human research on AOD-9604 is mixed. A 2013 review of six randomized, double-blind, placebo-controlled human trials reported AOD-9604 was generally well tolerated and did not show the same undesirable effects as full HGH (increased IGF-1, impaired glucose tolerance, insulin resistance, antibody formation in tested participants). Safety and effectiveness are not the same thing.

AOD-9604's development as an obesity drug did not succeed, the larger clinical program failed to demonstrate sufficient weight-loss efficacy. Reviews of obesity pharmacotherapy describe AOD-9604 as a growth hormone analog that failed to demonstrate efficacy in Phase 2b studies.

Strongest themes: fat-cell metabolism, lipolysis, anti-lipogenesis, fat oxidation in preclinical models, body-weight and fat-mass reduction in obese rodent models, beta-3 adrenergic pathway research, obesity drug-development research, and human safety/tolerability research. The weakest area is proven human weight-loss efficacy, commonly marketed for fat loss, but human clinical evidence does not support strong outcome claims.

AOD-9604 should be presented as a metabolic research peptide, not a proven weight-loss drug.

FDA lists compounded drugs containing AOD-9604 among substances that may present significant safety risks, possible immunogenicity for certain routes, peptide-related impurities, API characterization issues, insufficient repeated-dose toxicity information, and lack of adequate clinical data to support safety and effectiveness.

Not FDA-approved for weight loss, obesity treatment, fat loss, bodybuilding, anti-aging, metabolic health, recovery, or general wellness.

WADA lists growth hormone fragments, including AOD-9604 and hGH 176-191, as prohibited substances, relevant to tested athletes, fighters, professional competitors, military athletes, and anyone subject to anti-doping rules.

AOD-9604 is a synthetic human growth hormone fragment studied for fat metabolism, lipolysis, anti-lipogenesis, fat oxidation, beta-adrenergic pathway research, body-composition research, obesity-related metabolic pathways, and adipose tissue signaling.

AOD-9604 is best positioned as a metabolic research peptide involved in fat-cell signaling and obesity-related metabolism research.

Its strongest practical relevance is the study of how fat cells regulate fat breakdown, fat storage, and energy metabolism.

The most accurate framing is fat-metabolism and body-composition research, not guaranteed weight loss, appetite suppression, fat burning, obesity treatment, HGH replacement, anti-aging, bodybuilding enhancement, disease treatment, or proven human body recomposition.